Dr. Dason on selecting neoadjuvant or adjuvant therapy for patients with UTUC

“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.

In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.

Related Content:

Bladder CancerUTv
Study shows low public awareness of smoking as a risk factor for bladder cancer
FDA approval sought for N-803 in NMIBC
Nivolumab/ipilimumab falls short as frontline treatment in advanced urothelial carcinoma